<DOC>
	<DOC>NCT01773070</DOC>
	<brief_summary>A follow up study designed to obtain long term data on subjects who either achieved a sustained virologic response or did not achieve a sustained virologic response in an Abbott sponsored hepatitis C study.</brief_summary>
	<brief_title>A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study</brief_title>
	<detailed_description>A follow-up study to assess resistance and durability of response to three experimental drugs ABT-450/r, ABT-267, and ABT-333 in subjects who have participated in Phase 2 or 3 clinical studies with these agents for the treatment of chronic hepatitis C. The other primary purpose of the study is to assess for durability of treatment response and assess for drug resistance.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Subject has received at least one dose of ABT450, ABT333 or ABT267 in a prior Abbott HCV Phase 2 or 3 study which is being submitted as a US IND. The interval between the last dose of the Abbott DirectActing Antiviral Agent therapy from the previous clinical study and enrollment in Study M13102 must be no longer than 2 years. The subject must voluntarily sign and date the informed consent form. Subject completed the posttreatment period of an eligible prior study. The investigator considers the subject unsuitable for the study for any reasons. Receipt of any investigational product from Day 1 and while enrolled in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>